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Abstract
Background: Glycerophosphodiester phosphodiesterase 2 (GDE2) is a six-transmembrane protein that cleaves
glycosylphosphatidylinositol (GPI) anchors to regulate GPI-anchored protein activity at the cell surface. In the
developing spinal cord, GDE2 utilizes its enzymatic function to regulate the production of specific classes of motor
neurons and interneurons; however, GDE2’s roles beyond embryonic neurogenesis have yet to be defined.
Method: Using a panel of histological, immunohistochemical, electrophysiological, behavioral, and biochemistry
techniques, we characterized the postnatal Gde2−/− mouse for evidence of degenerative neuropathology. A
conditional deletion of Gde2 was used to study the temporal requirements for GDE2 in neuronal survival.
Biochemical approaches identified deficits in the processing of GPI-anchored GDE2 substrates in the SOD1G93A
mouse model of familial Amyotrophic Lateral Sclerosis that shows robust motor neuron degeneration.
Results: Here we show that GDE2 expression continues postnatally, and adult mice lacking GDE2 exhibit a slow,
progressive neuronal degeneration with pathologies similar to human neurodegenerative disease. Early phenotypes
include vacuolization, microgliosis, cytoskeletal accumulation, and lipofuscin deposition followed by astrogliosis and
cell death. Remaining motor neurons exhibit peripheral motor unit restructuring causing behavioral motor deficits.
Genetic ablation of GDE2 after embryonic neurogenesis is complete still elicits degenerative pathology, signifying
that GDE2’s requirement for neuronal survival is distinct from its involvement in neuronal differentiation. Unbiased
screens identify impaired processing of Glypican 4 and 6 in Gde2 null animals, and Glypican release is markedly
reduced in SOD1G93A mice.
Conclusions: This study identifies a novel function for GDE2 in neuronal survival and implicates deregulated GPI-
anchored protein activity in pathways mediating neurodegeneration. These findings provide new molecular insight
for neuropathologies found in multiple disease settings, and raise the possibility of GDE2 hypofunctionality as a
component of neurodegenerative disease.
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Background
Throughout life, neurons must contend with a multitude
of stresses both intrinsic and extrinsic. Supplied with only
a finite number from birth, and excluding a few notable
neurogenic niches [1, 2], the adult nervous system has no
method for the bulk replacement of a neuronal popula-
tion. As such, the nervous system must employ distinct
mechanisms to actively ensure neuronal health and
survival. What these mechanisms are and how they inte-
grate with cellular pathways are not well understood.
Moreover, identifying proteins responsible for neuronal
survival is crucial to understand the multifactorial patho-
genesis of human neurodegenerative disease.
The six-transmembrane glycerophosphodiester phos-
phodiesterases (GDEs) are a small family of three
proteins that are related to a larger group of one-pass,
two-pass and secreted proteins through common
possession of an enzymatic domain homologous to bac-
terial glycerophosphodiester phosphodiesterase (GDPD)
[3, 4]. Six-transmembrane GDEs consist of GDE2, GDE3
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and GDE6, and their enzymatic GDPD domains face the
extracellular space [3, 5]. During embryogenesis, GDE2,
also known as GDPD5, is expressed in postmitotic neu-
rons in the spinal cord and the brain. Functional studies
in the mouse and chick demonstrate that GDE2 is neces-
sary and sufficient for motor neuron generation. In the
developing chick spinal cord, overexpression of GDE2 in
motor neuron progenitors drives their premature differen-
tiation into postmitotic motor neurons, while ablating
GDE2 by RNA interference profoundly reduces motor
neuron differentiation [6, 7]. GDE2 plays analogous roles
in mammalian neurodevelopment. Gde2 knock out (KO)
mice fail to generate specific subsets of late born alpha
motor neurons as well as distinct populations of spinal
interneurons [8, 9]. In the brain, GDE2 loss leads to a
decrease in deep layer neurons but an expansion of upper
layer neurons [10]. Importantly, point mutations to critical
residues within the enzymatic GDPD domain abolish
GDE2’s ability to promote differentiation, demonstrating
the central role of extracellular enzymatic activity to
GDE2 function [6].
Glycosylphosphatidylinositol (GPI)-anchorage is a com-
mon post-translational modification employed to adhere
proteins to the extracellular leaflet of the plasma mem-
brane via covalent attachment of a lipid moiety to the
protein’s C-terminus [11]. Approximately 10–20% of all
cell surface protein is GPI-anchored while over 150
unique mammalian proteins have known GPI-anchorages
[12]. Activities of soluble versus membrane-tethered
GPI-anchored proteins differ, implying a critical role
for pathways that release GPI-anchored proteins from
the cell membrane. We have shown that GDE2 pos-
sesses the unique capacity to cleave within the GPI-
anchor of proteins tethered to the cell surface. During
motor neuron differentiation, GDE2 functionally inacti-
vates RECK (REversion-inducing Cysteine-rich protein
with Kazal motifs) by cleaving its GPI-anchor, releasing
it from the cell surface of motor neurons. This leads to a
non-cell autonomous decrease in Notch signaling in
neighboring progenitors, promoting cell-cycle exit and dif-
ferentiation. Similarly, GDE2 mediated cleavage of Glypi-
can 6 at the cell surface has recently been reported to
promote the differentiation of neuroblastoma cells [13].
GPI-anchor cleaving activities were also detected in GDE3
and GDE6, providing evidence that the six-
transmembrane GDEs are the first known GPI-anchor
cleaving enzymes in mammals that function at the cell
surface [9]. Interestingly, a number of GPI-anchored pro-
teins have been implicated in neurodegenerative disease.
For example, conversion of GPI-anchored cellular prion
protein into cytotoxic aggregates is a main focus in
Creutzfeld-Jacob disease [14]. Expression of GPI-anchored
CD59 has been shown to be neuroprotective in neurons
and decreased expression has been reported in the brains
of patients with Alzheimer’s Disease (AD) [15], and aber-
rant Glypican processing has been detected in the context
of AD and Niemann-Pick Disease [16, 17]. In Amyo-
trophic Lateral Sclerosis (ALS), expression of GPI-
anchored Ephrin A5 and uPAR are both significantly al-
tered [18, 19]. These observations underscore the
importance of GPI-anchor regulation in disease, and open
an avenue for GDE2 dysfunction to mediate aspects of
neurodegeneration.
Here, we find that aged Gde2 KO mice develop a pro-
tracted, progressive neurodegeneration afflicting spinal
motor neurons that resembles pathologies frequently
observed across human neurodegenerative settings [20,
21]. Timed ablation of GDE2 after motor neuron differ-
entiation is complete elicits neurodegeneration in adult
animals, indicating that GDE2 function in neuronal sur-
vival is distinct from its role in embryonic neurogen-
esis. In addition, we observe the reduced release of
Glypican proteins that are known substrates of GDE2
in SOD1G93A animals, which exhibit profound motor
neuron degeneration. This study identifies GDE2 as an
important regulator of neuronal survival in the adult
nervous system, and invokes the possibility that deregu-
lated GPI-anchored substrate activities are components
of motor neuron degenerative pathways.
Methods
Animal husbandry
Mice were maintained and used in accordance with
approved Johns Hopkins University IACUC protocols.
Gde2+/− and Gde2lox/+ mice with mixed backgrounds
(129/SV x C57BL/6J) were out-crossed to C57BL/6J
(Jackson Laboratories 000664) for four generations.
Gde2lox/+;ROSA:CreERmice were maintained on a C57BL/
6J background and crossed with Gde2−/− for conditional
ablation of Gde2. B6SJL-Tg(SOD1*G93A)1Gur/J mice
were obtained from Jackson Laboratory (Stock# 002726),
and maintained as a hemizygous line on a C57BL/6J back-
ground. Animals for 6 month motor neuron counts were
pooled from 6 to 7 month old animals. Genotyping
primers, competitive PCR analysis, and 4-OHT adminis-
tration are as previously described [8], and B6SJL-
Tg(SOD1*G93A)1Gur/J mice were genotyped as specified
by Jackson Laboratory.
Tissue preparation
Animals were anesthetized with Avertin solution (1.3%
2,2,2-Tribromorethanol (Fluka 90710) and 0.7% 2-
methyl-2-butanol (Sigma 240486) in Phosphate Buff-
ered Saline (PBS)) delivered via intraperitoneal injection
at 0.02 ml/g body weight. After confirming the absence
of a pain reflex, animals were transcardially perfused
with 0.1 M Phosphate Buffer (PB) followed by 4% para-
formaldehyde (PFA) in 0.1 M PB. Regions of interest
Cave et al. Molecular Neurodegeneration  (2017) 12:8 Page 2 of 20
were dissected and processed into cyromolds or paraffin
blocks. Cryosections: Tissue samples were post-fixed in 4%
PFA for 1 h at 4 °C, rinsed in PBS, and incubated in 30%
sucrose for 12–24 h. Samples were embedded in O.C.T
Compound (Tissue-Tek 62550–12) and flash frozen in a
dry ice ethanol bath. Cryomolds were stored at −80 °C
and sectioned on an UltraPro 5000 Cryostat (Vibratome).
Paraffin Sections: Tissue samples were post-fixed in 4%
PFA for 12–15 h at 4 °C, rinsed in PBS, and incubated in
Decalcifying Solution-Lite (Sigma D0818-1L) for 7 h at
room temperature. Samples were then dehydrated in a
graded ethanol series and cleared in Xylenes (Fisher Scien-
tific X3P-1GAL). Samples were then infiltrated in Blue
Ribbon Paraffin wax (Leica Microsystems 3801360) for
12–15 h and embedded. Sections were cut with a Rotary
Microtome (Leica RM2235). For staining, slides were
deparaffinized in Xylenes (Fisher Scientific X3P-1GAL),
and rehydrated in an ethanol series. After staining, fluor-
escent slides were dehydrated in ethanol and coverslipped
with Vectashield mounting medium (Vector Laboratories
H1000); pathology slides were cleared with Xylenes, and
coverslipped with Permount (Fisher Scientific SP15-500).
Pathology stains
Hematoxylin and Eosin: Sections were incubated in
Harris Hematoxylin (VWR 95057–858) for 8 min,
differentiated in 1% acid alcohol for 4 s, and incubated
in Bluing Reagent Solution (VWR 95057–852) for
2 min. Sections were then counterstained with Eosin-
phloxine solution (VWR 95057–846). For quantification,
a vacuolated neuron was defined as having 2 or more
clear somal abscesses greater than 2 μm in diameter. A
minimum of 200 neurons were analyzed per animal.
Sudan Black B: Sections were incubated in 1% Sudan
Black B (Sigma 199664-25G) in 70% ethanol for 2 min.
Kohler illuminated brightfield images were acquired on
an Axioskop 2 (Zeiss) with a Retiga 2000R CCD camera
(QImaging). Brightness and contrast were adjusted
equally between experimental conditions. Post-hoc color
balance was adjusted to achieve uniform white balance
on all images.
Fluorescent in-situ hybridization
In-situ hybridizations were performed with modifica-
tions from Schaeren-Wiemers and Gerfin-Moser, 1993
[22]. Briefly, endogenous peroxidase activity was blocked
with 0.3% hydrogen peroxide + 0.1% sodium azide.
Sections were acetylated in 0.5% acetic anhydride and
permeabilized with 0.1% Triton X-100 (Sigma T8787).
Slides were hybridized with digoxigenin-labeled probe
overnight at 65 °C in an RNAse free chamber. 680 bp
sense and antisense probes were generated from the 3′
UTR of mouse Gde2. After hybridization, sections were
washed with 50% formamide/sodium citrate buffers at
65 °C. Sections were treated with blocking buffer (Roche
11096176001) and incubated with sheep anti-digoxigenin-
POD, 1:250 (Roche 11207733910) overnight at 4 °C. Fluor-
escent signal was developed with the Tyramide Signal
Amplification Kit (PerkinElmer NEL741001KT) according
to the manufacturer’s instructions.
Immunohistochemistry
Sections were washed in Phosphate Buffered Saline + 0.3%
Triton X-100 (PBST) and microwave boiled in 10 mM so-
dium citrate, pH 6.0 for 10 min for antigen retrieval. Slides
were blocked with 5% bovine serum albumin and incu-
bated with primary antibodies overnight at 4 °C. Primary
antibodies were visualized with fluorescently conjugated
secondary antibodies (Jackson Immunoresearch). Whole
mount muscle staining was performed without antigen re-
trieval. Dissected muscle was incubated in primary anti-
body + Alexa 488 conjugated α-Bungarotoxin (Invitrogen
B13422) for 24 h at room temperature and incubated in
secondary antibody for 48 h at room temperature while
rotating. Confocal images were taken on a Zeiss LSM 700
with identical acquisition parameters between experimen-
tal groups. Any image contrast and brightness adjust-
ments were made equally between experimental groups.
GFAP area fraction was calculated in ImageJ by threshold-
ing regions of interest (ROI) above background and divid-
ing the area of the GFAP+ processes by the total ROI area
(150 μm2). Peripherin intensity measurements were taken
in ImageJ using a 7.5 μm2 ROI centered over the cell
soma. Antibodies used in this study: rabbit anti-GDE2,
1:1000 (Covance); goat anti-Choline Acetyltransferase,
1:100 (Millipore AB144P); mouse anti-NeuN, 1:200 (Milli-
pore MAB377); mouse anti-GFAP, 1:500 (BD Pharmingen
556328); rabbit anti-Neurofilament-H, 1:500 (Millipore
AB1989); rabbit anti-Peripherin, 1:400 (Millipore
AB1530); rabbit anti-Iba1, 1:500 (Wako 019–19741); rat
anti-Lamp2, 1:500 (DSHB ABL-93); rat anti-CathepsinD,
1:500 (R&D Systems MAB1029).
Motor neuron quantification
Motor neurons were quantified from paraffin sections
of lumbar (L3-L5) spinal cord. Alpha (ChAT+/NeuN+)
and gamma (ChAT+/NeuN−) motor neuron numbers
were averaged from a minimum of 15 sections and a
minimum of 140 neurons per animal to ensure accur-
ate sampling of heterogeneously distributed motor
neurons. Total neurons counted per time point:
13 months: control = 2249, Gde2 KO = 1573; 6 months:
control = 1674, Gde2 KO = 950. The LMC was defined
as all neurons in the lateral aspect of spinal lamina 7.
The MMC was defined as all neurons in the medial
portion of spinal lamina 8.
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Lipofuscin imaging
Autofluorescent lipofuscin particles were imaged in
unstained paraffin sections on a Zeiss LSM 700 using
a 405 nm excitation laser and a long-pass 505 nm
emission filter. Lipofuscin puncta were quantified
from a single, in-focus 0.7 μm z-plane from neurons
in the ventral horn. Lipofuscin spectra were measured
from in-situ deposits in paraffin embedded spinal cord
sections using a Zeiss LSM 510 equipped with a meta-
detector and a near-infrared tunable pulsed femtosec-
ond Ti:Sapphire laser (Chameleon Ultra II). Using 2-
photon excitation at 770 nm, the emitted light was
quantified in 10 nm increments from 367 nm to
699 nm with the meta-detector from the region of
interest. The excitation spectrum was estimated by
varying the 2-photon wavelength from 690 nm to
870 nm and measuring intensity of the emitted light
filtered through a 500–550 nm band pass filter. The
average intensity was then plotted using the approxi-
mate 1P wavelength (roughly λ/2).
Biochemistry
Lysate Preparation: Freshly dissected lumbar spinal
cord segments were lysed and separated into total and
membrane fractions as previously described to detect
Neurofilament and GDE2, respectively [9]. Sequential
Solubilization: Dissected lumbar spinal segments were
first homogenized in Tris Buffer (10 mM Tris, 150 mM
NaCl, pH 7.5) for 15 s with a Pellet Pestle (Kimble
749540). Samples were centrifuged 5000 x G for 5 min.
Supernatant (S1 fraction) was transferred to a new tube.
The insoluble pellet was homogenized in Tris Buffer +
60 mM Octyl β-D-glucopyranoside (Sigma O8001) for
15 s with a Pellet Pestle. Samples were centrifuged at
3000 x G for 5 min. Supernatant (S2 fraction) was
transferred to a new tube. Alpha Toxin Pull Down
Assay: Alpha toxin from Clostridium septicum was
expressed and purified as previously described [23] with
the following modifications. An N-terminal HaloTag +
C-terminal histidine tagged alpha toxin plasmid was
transformed in Rosetta (DE3)pLysS Escherichia coli.
Bacterial pellets were then resuspended in HaloTag
protein purification buffer (50 mM HEPES, 150 mM
NaCl, 1 mM DTT, 0.5 mM EDTA, and 0.005% IGEPAL
CA-630), supplemented with 0.2 mg/mL lysozyme,
0.5 mg/mL DNase I. Cells were lysed with repeated
rounds of freeze-thaw and centrifuged at 10,000 x G for
15 min at 4 °C. The supernatant was incubated with
TALON metal affinity resin (Clontech) overnight at
4 °C. Alpha toxin was eluted in 50 mM PB, 300 mM
NaCl, 150 mM imidazole, and the eluted sample was
dialyzed and incubated with HaloLink resin for 1 h at
room temperature. Proteins were then cross-linked
with 0.05 mg/mL DSS. Soluble protein extract from
WT and Gde2 KO mice were incubated with the cross-
linked alpha toxin overnight at 4 °C, and captured proteins
were eluted from the alpha toxin using 2% SDS. Western
Blot: Samples were run on 10% SDS-PAGE in Tris-glycine
buffer. Proteins were transferred to PVDF membrane,
washed with TBST, blocked with 5% milk, and probed
with the desired antibodies: rabbit anti-GDE2 (Convance
1:1000), rabbit anti-Neurofilament H (Millipore AB1989),
mouse anti-Actin (Millipore MAB1501R); rabbit anti-
Glypican 1 (Abcam AB55971), rabbit anti-Glypican 4
(Immundiagnostik AH1007.2), goat anti-Glypican 6 (R
and D Systems AF1053), rabbit anti-Na/K ATPase
(Abcam AB76020), rabbit anti-GAPDH (Cell Signaling
8884). Blots were developed using HRP-conjugated
secondary antibodies (Jackson Immunoresearch) with
a chemiluminescent substrate. Densitometry measure-
ments were made with ImageJ.
Mass spectrometry
Isolated gel pieces were subjected to a modified in-gel
trypsin digestion procedure [24]. Gel pieces were
dehydrated with acetonitrile for 10 min and then com-
pletely dried in a speed-vac. Gel pieces were rehy-
drated with 50 mM ammonium bicarbonate solution
containing 12.5 ng/μl modified sequencing-grade tryp-
sin (Promega) at 4 °C. The excess trypsin solution was
removed and replaced with 50 mM ammonium bicar-
bonate solution, and samples were then placed in a
37 °C room overnight. Peptides were later extracted by
removing the ammonium bicarbonate solution,
followed by one wash with a solution containing 50%
acetonitrile and 1% formic acid and dried. Samples
were reconstituted in 5–10 μl of HPLC solvent A
(2.5% acetonitrile, 0.1% formic acid). A nano-scale
reverse-phase HPLC capillary column was created by
packing 2.6 μm C18 spherical silica beads into a fused
silica capillary (100 μm inner diameter x ~30 cm
length) with a flame-drawn tip [25]. After equilibrating
the column each sample was loaded via a Famos auto
sampler (LC Packings) onto the column. A gradient
was formed and peptides were eluted with increasing
concentrations of solvent B (97.5% acetonitrile, 0.1%
formic acid). As peptides eluted they were subjected
to electrospray ionization and then entered into an
LTQ Orbitrap Velos Pro ion-trap mass spectrometer
(Thermo Fisher Scientific). Peptides were detected,
isolated, and fragmented to produce a tandem mass
spectrum of specific fragment ions for each peptide.
Peptide sequences were determined by matching pro-
tein databases with the acquired fragmentation pattern
using Sequest (Thermo Fisher Scientific) [26]. All da-
tabases include a reversed version of all the sequences
and the data was filtered to between a one and two
percent peptide false discovery rate.
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Electrophysiology
Animals were anesthetized under isofluorane anesthesia
and body temperature maintained at 37 °C with a heat-
ing pad. A subdermal ground electrode was positioned
in the upper back. Recordings were made with a Power-
Lab signal acquisition platform (ADInstruments).
Motor Nerve Conduction Study (MNCS): Compound
Motor Action Potentials (CMAPs) were obtained from
the animal’s right hindpaw. Platinum subdermal needle
electrodes (Grass Instruments) were placed in plantar
foot pads and stimulating electrodes were placed into
the sciatic notch. The average of 5 CMAPs evoked with
supramaximal stimulation was recorded. Motor Unit
Number Estimation: The lower hindlimb was fitted with
a circumferential surface electrode (CareFusion 019–
439300) lined with electroconductive gel (Parker Labora-
tories 15–60). Sequentially increasing stimulation was de-
livered with needle electrodes positioned in the sciatic
notch until discrete CMAPS were observed. The first 10
stable motor units were recorded per animal followed by
the supramaximal CMAP. Both hindlimbs of each animal
were tested. Sensory Nerve Conduction Study (SNCS):
Sensory Nerve Action Potentials (SNAPs) were recorded
by placing needle electrodes in the dorsal aspect of the
proximal tail and stimulating 5 cm distally. SNAP width is
the time required for the SNAP waveform to return to
baseline, and conduction velocity is calculated by dividing
the recording distance (5 cm) by the distal latency.
Behavior
Mouse behavioral tests were performed at the Johns Hop-
kins University Brain Science Institute Behavioral Core.
Male mice (10 WT and 10 Gde2 KO) were followed longi-
tudinally with evaluation at 6 months and 13 months.
Tests were performed sequentially; first grip strength, then
open field followed by heat sensitization. Each test was
done on a different day to reduce animal stress and fa-
tigue. Electrophysiological experiments (described above)
were performed after the behavior at each time point. To
minimize variability, tests were only performed by 1 per-
son between the hours of 11 am and 4 pm in the light
cycle. WT and KO animals were housed and tested to-
gether with unrestricted access to food and water. Prior to
the first test at each time point, animals were handled by
the experimenter for one hour on 5 consecutive days.
Open Field: Individual animals were recorded for 30 min
while they explored an open field activity chamber (Photo-
beam Activity System, San Diego Instruments). Movement
was measured as disruptions in a grid of infrared beams
lining the base of the chamber. During the recording, the
chambers were enclosed in ventilated, light-proof cabinets.
Grip Strength: Grip strength was measured by lifting the
animal by the tail so its forelimbs or hindlimbs can grab
the grid of the grip strength meter (Grip Strength Test,
IITC Life Science). When the animal is withdrawn, the
force of the grip is recorded by a force transducer. In a
session, each animal is tested 5 times with at least a
30 min rest in the home cage in between measurements.
Heat Sensitization: Animals are habituated in clear plexi-
glass enclosures resting on an elevated glass platform
heated to 32 °C (Plantar Test Analgesia Meter 390G, IITC
Life Science). Latency is recorded as the interval between
activating a heat lamp under the rear right paw and with-
drawal of the paw from the targeted position. Per session,
each animal is tested 7 times with at least 30 min of rest
on the platform between measurements.
Statistical analysis
All graphs represent mean ± SEM. Longitudinal behavior
experiments compared across multiple time points were
analyzed with a two-way Analysis of Variance (ANOVA)
with repeated measures. All other quantitative data was
analyzed with an unpaired Student’s t-test. Significance
level is a value of p ≤ 0.05. Cell counts in Fig. 6e, h, and
Additional file 1: Figure S2 are all normalized to the
mean of the control values for clarity of presentation.
Statistical analysis was performed on the raw data. The
n-numbers as stated in the figure legends refer to indi-
vidual animals processed and analyzed equivalently be-
tween the experimental groups.
Results
GDE2 is expressed in the postnatal spinal cord
To assess postnatal expression of Gde2, we performed
fluorescent in-situ hybridization (FISH) on lumbar spinal
cord sections using antisense and sense probes directed
against the 3′ untranslated region (UTR) of Gde2. In
1 month old Gde2+/+ mice, Gde2 mRNA expression is
widespread throughout the spinal cord. We detect Gde2
transcript in all spinal laminae, lateral and ventral funiculi,
and the dorsal columns (Fig. 1a). This cellular distribution,
particularly in the white matter, implies that postnatal
Gde2 expression is not confined to neuronal subtypes. We
observe clear Gde2 expression in large diameter neurons
in the ventral horn (Fig. 1b), small diameter neurons in
the dorsal horn (Fig. 1c), and glial soma in the white mat-
ter (Fig. 1d). Similar analysis using the corresponding
sense probe showed no signal in adjacent sections con-
firming specificity of the antisense probe (Fig. 1e). This ex-
pression pattern is consistent with published cell-type
expression databases documenting broad Gde2 expression
in the postnatal CNS [27, 28].
To confirm that GDE2 protein is produced postnatally,
we performed western blots of 1 month and 19 month
lumbar spinal cord lysates using an antibody generated
against GDE2. Gde2+/+ lysates show a strong band at the
predicted size that is absent in Gde2−/− littermates (Fig. 1f).
Taken together, these observations indicate that GDE2
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expression continues throughout life, suggesting ongoing
roles for GDE2 in the adult nervous system.
Gde2 null animals present degenerative pathology
To investigate the postnatal roles of GDE2, we analyzed
transverse sections of Gde2+/+ and Gde2−/− lumbar
spinal cords at 6 weeks and 19 months, two time points
which allow the comparison between early and late stage
pathology. Using Hematoxylin & Eosin (H&E) stains to
visualize cellular and interstitial morphology, we find
neurons in the Gde2−/− spinal cord are filled with intra-
cellular vacuoles that are not apparent in wild-type
(WT) animals (Fig. 2a–d). At 19 months, Gde2−/− motor
neurons are heavily vacuolated, with shrunken and con-
densed somas, and have separated from their adjoining
neuropil (Fig. 2d). We quantified the incidence of this
intracellular vacuolization among neurons in the ventral
horn. At 6 weeks, only 3.50 ± 1.09% of WT neurons con-
tain vacuoles compared to 14.02 ± 3.39% in Gde2−/−
mice. At 19 months, vacuolization among WT neurons
Fig. 1 Gde2 mRNA and protein are expressed in the postnatal spinal cord. a Paneled epifluorescent image of fluorescent in-situ hybridization
(FISH) using a Gde2 antisense probe showing broad expression in all spinal laminae (labeled I to X), as well as the corticospinal tract (CST), dorsal
columns (DC), lateral funiculus (lf), and ventral funiculus (vf). Scale bar = 100 μm. b–d Magnified regions indicated in panel A showing Gde2 ex-
pression in large diameter motor neurons (B), small diameter neurons (C), and glia (D). Arrows mark examples. Scale bar = 35 μm. e Gde2 sense
probe shows no signal in the lumbar spinal cord. Dashed yellow lines = boundary between grey and white matter. Scale bar = 150 μm. f Western
blot visualizing GDE2 protein (80kD band) in WT and not Gde2 KOs. n = 3
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climbs to 15.68 ± 1.03% and the incidence in the KO
rises to 47.41 ± 2.28% (Fig. 2e). In addition, aged Gde2−/−
animals exhibit prominent spongiform vacuoles in the
extracellular space of the dorsal columns and ventral
grey matter (Fig. 2f–i). We also observe instances of
satellitosis, the surrounding of neurons by smaller nuclei
that are presumptive macrophages in the processes of
phagocytosis (Fig. 2j–o) [29]. These phenotypes point to
a pronounced, progressive neuronal degeneration in the
absence of GDE2.
Gde2 deletion causes astrocytosis and microgliosis
Prompted by the pronounced satellitosis, we next ana-
lyzed Gde2−/− spinal cords for additional glial pathology.
Gliosis refers to the inflammatory reaction of glial cells,
mainly astrocytes and microglia, in response to injury or
disease and is a strong indicator of degeneration. As
astrocytes and microglia respond to disease conditions,
they undergo distinct morphological transitions. Inflam-
matory astrocytes expand and enumerate their processes
while microglia truncate their processes and form multi-
cellular aggregates [30, 31]. We analyzed astrocyte
morphology by staining for Glial Fibrillary Acidic Pro-
tein (GFAP). At 6 weeks, no appreciable differences are
detected in the ventral horn of Gde2−/− mice (Fig. 3a
and b); however, by 19 months, astrocytes in the Gde2
−/− animals show intensified GFAP immunoreactivity
and broadened processes (Fig. 3c and d). We quantified
the differences in astrocyte morphology by calculating
the area of all GFAP+ processes within a 150 μm2 region
of interest (ROI) centered in either the ventral grey mat-
ter or white matter (Fig. 3d). The area of the GFAP+
processes divided by the area of the ROI yields the
GFAP area fraction. At 6 weeks, the WT and KO values
for GFAP area fraction were 0.22 ± 0.12% and 0.11 ±
0.08% in grey matter and 10.21 ± 3.97% and 8.29 ± 3.12%
in white matter, respectively. At 19 months of age, the
WT and KO values were 0.40 ± 0.22% and 22.26 ± 4.15%
in grey matter and 13.86 ± 4.34% and 41.07 ± 6.40% in
white matter, respectively (Fig. 3e). Resting Iba1+
Fig. 2 Gde2 null animals develop vacuolization and satellitosis. a–d H&E staining of transverse sections of lumbar spinal cord. Arrows in c, d show
progressive intracellular vacuolization. Scale bar = 20 μm. e Quantification of increased neuronal vacuolization in large diameter ventral horn
neurons of the Gde2 KO. Graph represents mean ± SEM. 6 weeks *p = 0.022, 19 months *p = <0.001, Student’s t test, n = 3. f–i Arrows mark large
spongiform vacuoles in the dorsal columns and ventral horn. Scale bar = 60 μm. j–o Arrows mark satellitosis of ventral horn neurons of the Gde2
KO. Scale bar = 20 μm. n = 3 WT, 4 KO
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microglia exhibit a very stereotyped morphology; they
are evenly spaced with multiple thin branches extending
from the soma (Fig. 3f–k). In contrast, microglia in the
6 week old Gde2 KO spinal cord display shortened, con-
densed processes indicative of microglial activation
(Fig. 3l–n). By 19 months, the reactive morphologies
worsen and large microglial aggregates form in the ven-
tral and lateral funiculi (Fig. 3o–q). In addition, we note
that the inflammatory glia often associate with the
spongiform abscesses in the grey and white matter
(Fig. 3r–s’). Taken together, Gde2 ablation produces
prominent astro- and microgliosis, which suggests a pro-
gressive neuropathology in the Gde2 KO spinal cord.
Gde2 KO neurons exhibit cytoskeletal accumulation and
mislocalization
The neuronal pathology in the spinal cord motivated us
to screen Gde2−/− animals for cytoskeletal defects preva-
lent in neurodegenerative disease. In neurons, one of the
principal cytoskeletal components is Neurofilament, and
of the three main neurofilament isoforms (NF-L, NF-M,
NF-H), irregularities in NF-H expression have been most
Fig. 3 Astrocytosis and microgliosis in the Gde2 KO. a–d Immunostaining for GFAP in WT (a, c) and Gde2 KO (b, d). Dashed yellow lines =
boundary between grey and white matter. Scale bar = 100 μm. e 19 month Gde2 null grey and white matter have significantly elevated GFAP area
fraction. Graph represents mean ± SEM. 19 month Grey matter *p = 0.002, 19 month White matter *p = 0.013, Student’s t test, n = 3. Example ROI
positions are illustrated in panel d. f–q Confocal projections of Iba1+ microglia from the ventral horn of WT and Gde2 KO ventral horns. Arrowheads
indicate condensed microglial processes and arrows denote multicellular aggregations in the absence of Gde2. Scale bar = 15 μm. n = 3. r–s’ Examples
for GFAP+ astrocytes and Iba1+ microglial processes interacting with the spongiform vacuoles (dashed yellow circles) in the aged Gde2 KO
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frequently associated with neurodegeneration [32–34]. In
Gde2 null animals at 6 weeks, we observe increased NF-H
immunoreactivity within dilated neuronal processes
(Fig. 4a–f ). By 19 months, the magnitude of the cytoskel-
etal accumulation has risen in the ventral horn (Fig. 4g–l).
To more accurately quantify the NF-H increase, we
performed western blots of 17 month lumbar spinal cord
lysates. We found a 2.25 ± 0.50 fold increase of NF-H
protein expression in Gde2 null spinal cords compared
with WT (Fig. 4m). Peripherin is an intermediate filament
expressed in motor, sensory, and sympathetic neurons and
has also been reported to undergo degeneration
dependent increases [35]. Unlike the bulk accumulation of
NF-H, neurons lacking Gde2 amassed peripherin protein
within their somas at 6 weeks (Fig. 4n and o). At
19 months, we detect the majority of peripherin immuno-
reactivity in the ventral and lateral funiculi within axons.
WT axons distribute peripherin in discrete bundles; Gde2
−/− axons traffic peripherin to the interior perimeter of the
axon (Fig. 4p–s”). Considering the importance of regulat-
ing cytoskeletal proteins for intracellular trafficking, the
dysregulation of NF-H and peripherin pose a severe im-
pediment to normal cellular function and likely reflect di-
minished neuronal health.
Fig. 4 Gde2 KO neurons show cytoskeletal dysregulation. a–l Neurofilament-H immunostaining in the ventral horn. Arrows indicate cytoskeletal
accumulation in the absence of Gde2. Arrowheads mark spheroid deposits of Neurofilament-H within dilated neuronal processes. Scale bar a, b, g,
h = 25 μm. Scale bar c-f, i-l = 15 μm. m Western blot quantifying increased NF-H protein. Graph represents mean ± SEM, *p = 0.004, Student’s t
test, n = 3 WT, 4 KO. n–q Gde2 null neurons accrue peripherin protein. Arrows indicate peripherin tendrils in the cell body at 6 weeks and axons
at 19 months. Scale bar = 25 μm. r–s” Arrowheads denote axonal accumulation of peripherin enriched around the perimeter of the axon. Scale
bar = 10 μm. n = 3
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Gde2 KO neurons have accelerated lipofuscin deposition
The degenerative accrual of NF-H and peripherin led us
to investigate whether Gde2 deletion promotes the patho-
logic accumulation of lipids as well as protein. Sudan
Black B is a lipophilic dye that intercalates into lipid rich
domains [36]. At 19 months, Gde2−/− neurons in the ven-
tral horn have pronounced perinuclear deposits that
strongly take up Sudan Black B that are not detectable in
Gde2+/+ neurons (Fig. 5a–d). These particles are charac-
teristic of lipofuscin, an accumulation of lipids and un-
digested cellular debris, namely proteins, which collect as
discrete cytosolic puncta during normal aging [37, 38].
Lipofuscin can be specifically visualized as autofluorescent
granules with ultraviolet absorbance and broad emission
in unstained tissue sections [36]. At 6 weeks of age, we de-
tect an average of 6.68 ± 2.28 autofluorescent lipofuscin
Fig. 5 Lipid deposition in Gde2 null neurons. a–d Sudan Black B darkly stains lipid deposits in motor neurons of the aged Gde2 KO (arrows). Scale
bar = 7 μm. n = 3. e–h Lipofuscin (arrows) is visualized as autofluorescent granules using ultraviolet excitation (405 nm) and a long pass emission
(LP 505) filter. Scale bar = 10 μm, n = 3. i Quantification of elevated lipofuscin granules at 6 weeks *p = 0.028 and 19 months *p < 0.001, Student’s t
test, n = 3. Graph represents mean ± SEM. j Lipofuscin granules have an ultraviolet excitation maxima centered at 390 nm, and a broad emission
curve peaking at 530 nm. k, l, m, n, o, p Lipofuscin association with lysosomes labeled by Lamp2 or CathepsinD. Scale bar = 4.25 μm. k’, l’, m’, n’,
o’, p’ Magnification of boxed regions in panels k-p. Lipofuscin is fully or partially colocalized with (filled arrows), surrounded by (arrowheads), or
devoid of (open arrow) lysosomal signal. Scale bar = 1.5 μm. n = 4
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granules per neuron in the KO and 0.47 ± 0.18 granules
in control neurons (Fig. 5e, f and i). At 19 months, nu-
merous bright autofluorescent granules are evident in
ventral horn neurons in Gde2 KO animals compared
with WT, 35.82 ± 1.69 versus 4.83 ± 0.84 granules, re-
spectively (Fig. 5g–i). These deposits have a spectral ex-
citation and emission profile consistent with lipofuscin
(Fig. 5j). Lipofuscinogenesis is nucleated by the lyso-
some, wherein reactive hydroxyl radicals form aldehyde
cross linkages between the undigested macromolecules
[38]. If the autofluorescent granules seen in the Gde2 KO
are lipofuscin, we predicted that a subset should colocalize
with lysosomal markers. Indeed, we find that some lipo-
fuscin granules are fully or partially colocalized with
Lamp2+ or CathepsinD+ lysosomes while others are juxta-
posed, and some have no lysosomal signal (Fig. 5k–p’).
Early accumulation of lipofuscin is an indicator of in-
creased cellular stress and can presage neurodegeneration
in disease conditions [39]. The advanced deposition of
lipofuscin granules in Gde2−/− animals provides further
evidence that GDE2 is essential for neuronal health.
Gde2 ablation causes progressive motor neuron loss
The collective histology in the Gde2−/− spinal cord signifies
a progressive neuropathology that worsens from 6 weeks
to 19 months afflicting neurons in the ventral horn of the
spinal cord. We next sought to understand if and how
these pathologies impact neuronal survival. Though the
pathology affects many neuronal subtypes in the ventral
horn, we focused on motor neurons as their cell death
is an integral component of many neurodegenerative
diseases. We assessed the survival of alpha motor neu-
rons (α) and gamma motor neurons (γ) in the lateral
and medial motor columns (LMC and MMC) of the
lumbar spinal cord. Alpha motor neurons innervate
force generating skeletal muscle while gamma motor
neurons innervate intrafusal muscle fibers to control
proprioceptive sensory feedback [40]. Both types of
motor neurons express Choline Acetyltransferase
(ChAT) but only alpha motor neurons coexpress NeuN
(Fig. 6a–b”) [41]. To understand how the progressive
neuropathology that develops from 6 weeks to
19 months affects cell survival, we quantified motor
neurons at 2 intermediate time points, 6 months and
13 months. In the LMC, which innervates limb mus-
cles, we find a marked decrease in both alpha and
gamma neurons (Fig. 6c–d”). At 6 months, we register
a 45.84 ± 4.75% decrease in alpha motor neurons and a
45.07 ± 9.75% decrease in gamma motor neurons
(Fig. 6e). By 13 months, these deficits grow to 61.91 ±
1.21% and 57.83 ± 1.87% for alpha and gamma, respect-
ively (Fig. 6e). In the MMC, which innervates the axial
muscles of the trunk, no decreases in alpha and gamma
motor neurons are detected at 6 months; however,
significant reductions are evident by 13 months of age
with alpha motor neurons falling 35.83 ± 6.57% and
gamma motor neurons dropping by 42.25 ± 3.03% in
the Gde2 KO (Fig. 6f–h). Thus, deletion of Gde2 results
in the progressive loss of spinal motor neurons as the
animal ages.
Gde2 KO animals undergo peripheral restructuring
without impaired peripheral nerve conduction
To determine if any physiological consequences result
from the motor neuron deficits in the Gde2 KO, we
carried out a longitudinal electrophysiological study of
peripheral nerve function in a cohort of 10 WT and 10
Gde2 KO mice. Considering the significant motor
neuron loss observed at 6 months and 13 months, we
performed Motor Nerve Conduction Studies (MNCS) at
these time points to screen for defects in peripheral
nerve physiology. MNCS record a Compound Motor
Action Potential (CMAP) from the plantar foot muscles
after stimulating the sciatic nerve (Fig. 7a). The latency
and amplitude of the CMAP convey the efficiency of
action potential conduction and strength of the neuromus-
cular connection, respectively [42]. At 6 and 13 months,
Gde2 KO animals displayed no changes in CMAP wave-
forms (Fig. 7b), indicating preserved peripheral nerve func-
tion in the absence of Gde2.
We next measured the size of the individual motor
units, defined as a motor axon and all the muscle fibers
it innervates, using Motor Unit Number Estimation
(MUNE). MUNE records from all the muscles of the
lower hindlimb and utilizes sequential increases in sub-
maximal stimulation to reveal individual CMAPs in a
quantal manner, each representing one motor unit. After
recording the amplitude of several motor units and div-
iding their average into the supramaximal CMAP, the
number of motor units in the recording field can be esti-
mated [43, 44]. We recorded the first ten stably detectable
CMAPs from 13 month WT and Gde2 nulls (Fig. 7c). The
average motor unit amplitude increases from 0.0274 ±
0.005 mV in the WT to 0.0781 ± 0.015 mV in Gde2−/− ani-
mals (Fig. 7d). There is no change in the supramaximal
CMAP; consequently, the MUNE values for WT and
Gde2 nulls are 96.48 ± 19 and 27.14 ± 5.23 motor units re-
spectively (Fig. 7d). The decrease in motor units in Gde2
−/− animals is consistent with peripheral restructuring ob-
served during long-term progressive motor neuron loss,
which involves reinnervation of denervated muscle fibers
by sprouting collaterals [45].
Gde2 KO animals have impaired motor performance
Considering the neuronal loss, peripheral restructuring
and histopathology of animals lacking GDE2, we mea-
sured the motor performance of our in-vivo cohort at
6 months and 13 months. When elevated by the tail,
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WT mice extend their hindlimbs away from their abdo-
men (Fig. 8a and b); however, the aged Gde2 null mice
display intermittent clasping of their hindlimbs consist-
ent with motor neuropathy (Fig. 8c and d) [46]. Grip
strength, the force that mice exert on a grid with their
paws when lifted away [47], showed no difference at
6 months (Fig. 8e). However at 13 months, we observed
a 31.52 ± 3.11% and 35.44 ± 3.63% decrease in forelimb
and hindlimb grip strength, respectively (Fig. 8e). As
with grip strength, we saw no changes in motor activity
in an open field chamber [48] at 6 months but found a
73.47 ± 14.95% decrease in fine movement at 13 months
(Fig. 8f ). Lastly, we measured heat sensitization, the ani-
mal’s latency to withdraw its hindpaw from a noxious
radiant heat source [48]. Successful completion of this
task requires a functional sensorimotor reflex circuit,
composed of a primary sensory neuron signaling to a
motor neuron which in turn signals to the limb muscles.
Gde2 KO mice have an increased latency to withdraw
their paw (5.51 ± 0.31 s versus 3.91 ± 0.52 s for the WT) as
early as 6 months, and comparable delays are seen at
13 months of age (Fig. 8g), indicating deficits within the
spinal sensorimotor reflex circuit. Considering the Gde2
KO’s impaired heat sensitization, a task requiring sensory
and motor function, we assayed primary sensory neurons
of the dorsal root gangion (DRG) for evidence of path-
ology. We find that lumbar DRG neurons in the Gde2 KO
display analogous pathology to motor neurons, including
Fig. 6 Gde2 KO mice have progressive motor neuron loss. a–b” Example images of alpha (α) and gamma (γ) motor neurons. Alpha motor
neurons are ChAT+/NeuN+ while gamma motor neurons are ChAT+/NeuN−. Arrows indicate position of the nucleus. Scale bar = 10 μm. c–d”
Representative images of motor neurons in the LMC labeled with ChAT and NeuN at 13 months. Example α and γ motor neurons are indicated.
Scale bar = 50 μm. e Quantification of LMC motor neuron loss. 6 months: α *p = 0.001, γ *p = 0.048, Total *p = 0.003, n = 3. 13 months: α *p <
0.001, γ *p = 0.046, Total *p = 0.001, n = 5. f–g” Images of α and γ motor neurons in the MMC at 13 months. h Graph quantifying MMC motor
neuron decrements. 6 months: α p = 0.212, γ p = 0.151, Total p = 0.116, n = 3. 13 months: α *p = 0.002, γ *p < 0.001, Total *p = 0.002, n = 5. All
graphs represent mean ± SEM, Student’s t test
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vacuolization, lipid accumulation, and cytoskeletal
dysregulation. As with efferent motor nerve conduc-
tion (Fig. 7b), we saw no changes in afferent periph-
eral sensory nerve conduction. (Additional file 1:
Figure S1). These collective observations suggest that
loss of GDE2 results in progressive erosion of sensori-
motor function in the adult animal.
GDE2 is required postnatally for neuronal survival
GDE2 is necessary during embryogenesis for promoting
the differentiation of late-born alpha motor neurons
within the limb-innervating LMC [8]. Aged Gde2 KO ani-
mals show losses in LMC alpha motor neurons beyond
the embryonic decrement and also exhibit reductions in
gamma motor neurons and MMC motor neurons, two
populations whose development is not impacted by Gde2
deletion (Fig. 6e and h) [8]. These observations suggest
that the degenerative loss of motor neurons in adult Gde2
−/− animals is not a latent effect of improper embryonic
development. To test this hypothesis, we utilized Cre-lox
approaches to ablate Gde2 after motor neuron
differentiation, which is normally complete by E11.5. Spe-
cifically, a floxed conditional allele of Gde2 (Gde2lox/-) was
used in concert with an inducible CreER driven by the ubi-
quitously expressed ROSA promoter (ROSA:CreER) [49],
and 4-hydroxytamoxifen (4-OHT) was delivered to preg-
nant dams at E17.5.
We aged Gde2lox/-;ROSA:CreER and Gde2+/−;ROSA:C-
reER littermate controls to 6 weeks and first verified the
efficient deletion of GDE2 at the functional and genetic
level. Confirming the efficacy of temporal ablation after
developmental neurogenesis is complete, the develop-
mental reduction of LMC alpha motor neurons nor-
mally observed at 6 weeks in constitutive Gde2 nulls is
not present in Gde2lox/-;ROSA:CreER animals. Further,
we verified the efficient ablation of the Gde2 condi-
tional allele using a competitive PCR strategy [8, 50]
that shows near complete removal of the Gde2 lox al-
lele following 4-OHT administration (Additional file 1:
Figure S2). We then analyzed these mice for the earliest
signs of neurodegeneration exhibited by constitutive
Gde2 nulls at this time point, i.e. vacuolization, increased
Fig. 7 Gde2 KO animals exhibit motor unit restructuring with equivalent peripheral conduction. a Example Compound Motor Action Potentials
recorded from WT and Gde2 KO hindpaws following supramaximal stimulation to the sciatic nerve. b Graphs measuring Distal Latency: 6 months
p = 0.413, 13 months p = 0.457; and Amplitude: 6 months p = 0.356, 13 months p = 0.388, n = 10. c Motor Unit field recordings from lower
hindlimb following incremental (grey traces) and supramaximal (black traces) stimulation of the sciatic nerve. d Graphs quantifying mean Motor
Unit Amplitude *p = 0.002, Supramaximal CMAP Amplitude p = 0.144, and Motor Unit Number Estimate *p = 0.026, n = 5. All graphs represent
mean ± SEM, Student’s t test
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cytoskeletal protein, lipofuscin, and microgliosis. H&E
staining revealed increased vacuolization in Gde2lox/-
;ROSA:CreER motor neurons that is not seen in Gde2
+/−;ROSA:CreER littermates (Fig. 9a and b). The inci-
dence of vacuolization among ventral horn neurons rose
from 10.25 ± 3.10% in the Gde2+/−;ROSA:CreER mouse to
26.56 ± 2.47% in the Gde2lox/-;ROSA:CreER (Fig. 9c). We
found that Gde2lox/-;ROSA:CreER animals showed a sub-
stantial increase in somal peripherin immunoreactivity
compared to controls (Fig. 9d and e). Mean peripherin in-
tensity levels increased from 52.85 ± 2.66 artificial fluores-
cence units (A.F.U) in Gde2+/−;ROSA:CreER neurons to
87.34 ± 9.12 A.F.U. in the Gde2lox/-;ROSA:CreER mouse
(Fig. 9f). Similarly, the average number of lipofuscin gran-
ules per neuron increases from 2.75 ± 0.56 in Gde2
+/−;ROSA:CreER mice to 9.62 ± 1.18 in Gde2lox/-;ROSA:C-
reER animals (Fig. 9g-i). The conditional ablation of Gde2
in the postnatal animal also reproduces the aberrant
microglial morphology seen in the constitutive KO at
6 weeks. Gde2lox/-;ROSA:CreER microglia have swollen
soma and less elaborate arborizations (Fig. 9j-q). Gde2lox/-
;ROSA:CreER also exhibit satellitosis of neurons within the
ventral horn (Fig. 9r–u). Taken together, these data
indicate GDE2’s function in preventing neurodegeneration
is distinct from its role in regulating motor neuron
differentiation.
Release of GPI-anchored GDE2 substrates is impaired in
the SOD1G93A mouse model of ALS
Our findings indicated that postnatal GDE2 function is
critical to prevent degeneration, and raise the possibil-
ity that impaired GPI-anchor cleavage mediates neuro-
degeneration. To discover GPI-anchored proteins
regulated by GDE2, we conducted an unbiased prote-
omic screen using alpha-toxin from Clostridium septi-
cum which specifically binds to GPI-anchors [23]. We
prepared non-membrane CNS extracts from aged WT
and Gde2 KO mice and used alpha-toxin to pull down
GPI-anchored proteins that were released from the
membrane. Protein complexes that yielded more signal
in the WT, indicative of impaired GPI-anchor cleavage
in the Gde2 KO, were then identified using mass
spectrometry. This screen identified two members of
the Glypican family of heparin sulfate proteoglycans,
Glypican 6 and Glypican 4, and both of these GPI-
anchored proteins have been reported as substrates of
Fig. 8 Gde2 ablation causes progressive motor degeneration. a–d Aged Gde2 KO animals display hindlimb clasping. e Grip strength shows
significant interaction with genotype and animal age (F1,39 = 9.016, *p = 0.008) indicating progressive deterioration of Gde2 KO motor
performance. f Fine movement in the Open Field Activity Monitor reveals significant interaction with genotype (F1,39 = 4.45, *p = 0.049). g
Heat sensitization shows significant increases at 6 months and 13 months in Gde2 KOs (F1,39 = 19,749, *p < 0.001, n = 10). Graphs represent
mean ± SEM, 2-way repeated measures ANOVA, n = 10
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GDE2 [9, 13]. We hypothesized that if the production
of non-membrane bound Glypican 4 and Glypican 6 via
GPI-anchor cleavage was crucial to prevent degeneration,
we should see diminished production of these proteins in
mouse models that exhibit motor neuron degeneration.
The SOD1G93A transgenic mouse models familial ALS and
shows profound motor neuron degeneration [51]. Al-
though less severe, degeneration in Gde2 nulls has consid-
erable phenotypic overlap with the SOD1G93A model,
namely vacuolization, neurofilament inclusions, gliosis, and
motor neuron death [52, 53].
We aged SOD1G93A mice and their non-transgenic lit-
termates (WT) to four months, an age with marked neu-
rodegeneration, and separated protein samples from
lumbar spinal cord extracts on the basis of hydrophobicity
using sequential solubilization. We first produced an S1
fraction by solubilizing hydrophilic proteins in Tris buffer,
and next an S2 fraction via solubilization of hydrophobic
Fig. 9 Gde2 is required postnatally to prevent neurodegeneration. a, b H&E staining shows increased vacuolization in Gde2lox/-;ROSA:CreER motor
neurons (arrows). Scale bar = 10 μm. c Quantification of increased vacuolization in Gde2lox/-;ROSA:CreER mice. *p = 0.007, n = 3. d, e Peripherin
immunoreactivity is increased in motor neurons of Gde2lox/-;ROSA:CreER animal (arrows). Scale bar = 10 μm. f Graph quantifying increased
peripherin signal in artificial fluorescence units (A.F.U). *p = 0.011, n = 3. g, h Enhanced lipofuscin accumulation is seen with the postnatal ablation
of Gde2 (arrows). Scale bar = 5 μm. i Quantification of lipofuscin granules per neuron. *p = 0.002, n = 3. Graphs represent mean ± SEM, Student’s t
test. j–q Conditional ablation of Gde2 induces aberrant microglial morphology (arrows), visualized by Iba1 staining. Scale bar = 10 μm. r–u
Gde2lox/-;ROSA:CreER exhibit satellitosis (arrows) comparable to the constitutive Gde2 KO. Scale bar = 20 μm. See also Additional file 1: Figure S2
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proteins in a buffer containing 60 mM Octyl β-D-
glucopyranoside [54] (Fig. 10a). We confirmed the effect-
ive enrichment of non-membrane protein in the S1 frac-
tion and membrane protein in S2 by performing western
blots which show that GAPDH, a hydrophilic cytosolic
protein, separates into S1, and Na/K ATPase a hydropho-
bic transmembrane protein separated into S2 (Fig. 10b).
Since impaired membrane release of a GPI-anchored pro-
tein would reduce S1 levels, we compared Glypican 6 and
Glypican 4 amounts in WT and SOD1G93A S1 fractions.
We observe that SOD1G93A mice have reduced levels of
Glypican 6 and Glypican 4 to 52.98 ± 14.87% and 38.82 ±
18.68% of control mice, respectively (Fig. 10c and d). In
addition, we examined Glypican 1, a family member that
has been connected with neurodegeneration in the con-
text of Niemann-Pick Disease [17]. Similarly, we find that
S1 Glypican 1 levels in the SOD1G93A spinal cord are
reduced to 39.77 ± 10.73% of control littermates (Fig. 10c
and d). These results indicate that the release of GPI-
anchored Glypican 6, 4 and 1 is abated in the degenerating
SOD1G93A mouse.
Discussion
This report identifies a novel function for GDE2 in neur-
onal survival in the adult nervous system that is distinct
from its function in embryogenesis. As early as 6 weeks,
Gde2 null animals exhibit pathologies analogous to hu-
man neurodegeneration including: intracellular vacuoli-
zation, microgliosis, accrual of cytoskeletal protein and
deposition of lipofuscin. Later in life, Gde2 KO animals
show progressive reductions in motor neuron numbers,
astrogliosis, and the appearance of spongiform vacuoles.
Loss of motor neurons elicits peripheral sprouting
evident by increases in motor unit size, culminating in
Fig. 10 GDE2 substrates show impaired release in SOD1G93A mice. a Schematic of the sequential solubilization protocol used to separate
hydrophilic non-membrane proteins (S1) from hydrophobic membrane proteins (S2). b Western blot demonstrating the successful enrichment of
non-membrane protein (GAPDH) in the S1 fraction and membrane protein (Na/K ATPase) in the S2 fraction for WT and SOD1G93A transgenic mice.
c Western blots visualizing the impaired production of non-membrane bound (S1) Glypican 6, Glypican 4, and Glypican 1 in the lumbar spinal
cord of 4 month SOD1G93A mice. d Quantification of the reduced membrane release of Glypican 6, *p = 0.038; Glypican 4, *p = 0.016; and Glypican
1, *p = 0.030 relative to GAPDH. Graph represents mean ± SEM. Student’s t test, n = 4 WT, 4 SOD1G93A
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deficits in motor behavior. Further, we show decreased
membrane release of GPI-anchored GDE2 substrates be-
longing to the Glypican family in the SOD1G93A mouse
model of familial ALS, suggesting that impaired GPI-
anchor cleavage may mediate aspects of motor neuron
degeneration.
Postnatal versus embryonic functions of GDE2
GDE2 is expressed in spinal motor neurons during em-
bryonic development and induces neighboring progen-
itors to differentiate into postmitotic motor neurons
[6, 8]. We find that adult Gde2 KO animals exhibit
progressive spinal motor neuron degeneration. Though
our analysis has focused on the lumbar spinal cord,
comparable pathology is evident at cervical and thor-
acic levels. Gde2 KO animals show an erosion of motor
function over time, consistent with the age-dependent
degeneration and loss of motor neurons in these ani-
mals. Our data argue against the possibility that loss of
GDE2 during embryogenesis is responsible for the
neurodegeneration observed in adult Gde2−/− animals.
During neurogenesis, Gde2 ablation disrupts the gen-
eration of late born alpha motor neurons within the
LMC that innervate limb musculature; however, no
changes are seen in MMC motor neurons which innervate
axial muscles nor gamma motor neurons which regulate
muscle stretch [8]. In contrast, cell loss in the adult Gde2
KO encompasses alpha and gamma LMC neurons by
6 months and MMC neurons by 13 months. Thus, motor
neuron degeneration in the adult Gde2 KO involves motor
neuron subtypes that are not dependent on GDE2 for
their initial generation. In addition, selective ablation of
GDE2 using an inducible CreER system after motor
neuron differentiation is complete still elicits neurodegen-
erative pathology. These collective observations suggest
that GDE2 function in neuronal survival is distinct from
its earlier role in controlling neurogenesis and is attribut-
able to postnatal GDE2 expression in the nervous system.
We note that GDE2 is also expressed in layer V cortical
neurons [10]; it will be interesting to determine whether
these neurons degenerate in the absence of GDE2 and if
they also contribute to the motor deficiencies of Gde2 KO
animals.
Published profiling studies combined with our in-situ
hybridization analyses show that postnatal GDE2 ex-
pression is not confined to neurons [27, 28]. While a
cell-autonomous role for GDE2 in neurons is feasible,
there is a growing body of literature implicating glia in
neurodegeneration. Astrocytes, oligodendrocytes, and
microglia have been identified as active components in
the degeneration of neurons seen in mouse models of
Amyotrophic Lateral Sclerosis (ALS) [55, 56] and
Alzheimer’s Disease [57]. Moving forward it will be
important to define the requisite cellular source of
GDE2 for neuronal survival.
GDE2 acts centrally to mediate neuronal survival
Neurodegeneration can initiate within the CNS or
begin in the periphery and progress in a retrograde
fashion towards cell bodies in the CNS, a process
known as Wallerian-like degeneration [58]. Our study
suggests that the degenerative pathology observed in
Gde2 KOs is not a consequence of Wallerian-like de-
generation but is likely to initiate within the CNS it-
self. Analysis of quadriceps muscles in the Gde2 KO
does not reveal evidence of irregular neuromuscular
junction (NMJ) morphology or denervated terminals
at 19 months, a time when degenerative pathology is
evident within neuronal cell bodies (Additional file 1:
Figure S3). Moreover, we did not observe deficits in
peripheral conduction times or action potential ampli-
tude, indicating that peripheral axons, Schwann cells,
and NMJs are relatively healthy. Further, mice lacking
Gde2 take longer to respond in a heat sensitization
assay, a behavior that requires functional central and per-
ipheral components. While this test cannot pinpoint
which element of the sensorimotor reflex produces the la-
tency, normal motor performance at 6 months and the in-
tegrity of peripheral nerve conduction suggest a defect in
the central integration of the nociceptive signal rather
than peripheral dysfunction. Taken together, these data
imply that GDE2 functions centrally to maintain neuronal
health and viability.
Pathways regulated by GDE2 activity
Our developmental studies of GDE2 function identify
GDE2 as a transmembrane enzyme that utilizes its extra-
cellular enzymatic domain to cleave GPI-anchors that
tether proteins to the membrane. Importantly, GDE2 and
its family members GDE3 and GDE6 are the only known
GPI-anchor cleaving enzymes in vertebrates that function
at the cell surface, and accordingly, are key regulators of
GPI-anchored protein activity at the plasma membrane
[9]. This implies that GDE2 enzymatic regulation of spe-
cific GPI-anchored proteins is central to its function in
neuronal survival. We conducted a proteomic screen to
identify GPI-anchored substrates of GDE2 and found Gly-
pican 4 and 6, both of which have been reported as GDE2
substrates [9, 13]. We then demonstrated that the non-
membrane versions of these proteins, as well as Glypican
1, are reduced in SOD1G93A mice. These results support
the hypothesis that the proper regulation of GPI-anchored
proteins is crucial for neuronal survival. Moreover, they
highlight Glypicans as potential components of pathways
essential for neuronal viability whose dysfunction could
lead to neurodegeneration. Investigating the role of GPI-
anchored GDE substrates including Glypicans will be of
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major interest as we continue to define the molecular
basis of neurodegeneration in Gde2 KO animals as well as
other models of degeneration.
How GDE2 mediates neuronal survival is a major out-
standing question. Clues to the intracellular processes in-
volved can be gleaned from the early degenerative
phenotypes. Gde2 KOs accumulate lipofuscin that is often
associated or adjacent to Lamp2+ or CathepsinD+-
lysosomes. Lipofuscin is a complex mixture of oxidized
protein, lipid degradation products, carbohydrates, and
metals that is deposited during aging; however, the strik-
ing appearance of lipofuscin in Gde2 null animals at
6 weeks is in line with a diseased neurodegenerative state
rather than normal aging. Lipofuscin accumulation
taxes lysosomal function and continually strains cellular
clearance, [38] which can produce dire consequences
for neuronal function and survival. Impaired cellular
clearance may also generate the excess cytoskeletal pro-
tein in the Gde2 KO. Disruptions in the cytoskeleton
will impair intercellular membrane trafficking, poten-
tially causing vacuolization. As this process begins to
mount, first microglia and subsequently astrocytes be-
come activated in response to neuronal stress, and as
neurons die they are phagocytosed during satellitosis.
Importantly, this model is compatible with the ex-
tended, progressive degeneration seen in the Gde2 KO
as chronic burdens on cellular clearance can slowly de-
teriorate neuronal health over time [38]. Future experi-
ments will address the precise interrelation of the early
Gde2 null pathology to better understand which subcel-
lular processes instigate the degeneration.
GDE2 and disease
This report shows GDE2, a GPI-anchor cleaving enzyme
previously identified as necessary for embryonic neuronal
differentiation, is a novel survival factor for motor neurons
in the postnatal spinal cord, and provides new insight into
the fundamental mechanisms governing neuronal survival.
Could GDE2 hypofunctionality be an unrecognized com-
ponent in human disease? Although Gde2 is expressed in
humans [59], no disease pedigrees have been linked with
mutations in Gde2. However, GDE2 could be functionally
inhibited in disease conditions, producing pathology
without registering mutations at the genomic level.
GDE2 activity is highly sensitive to cellular redox states.
High oxidative conditions in the endoplasmic reticulum
oxidize cysteine residues within the GDE2 enzymatic
domain and prevent GDE2 trafficking to the cell sur-
face [60]. In addition, GDE2 activity at the cell surface
can be inhibited by oxidation of cysteine residues within
the intracellular N- and C-termini [7]. We speculate that
increased ROS levels in disease conditions could lead to
thiol-redox dependent inhibition of GDE2 trafficking and/
or activity that would impinge on its function in neuronal
survival. Importantly, elevation of reactive oxygen species
(ROS) and oxidative stress are prevalent in many neurode-
generative diseases [61–64], broadening the potential for
GDE2 inhibition in disease.
Gde2 was recently identified in a network analysis
that generated a broad “HSPome” of potential targets of
Hereditary Spastic Paraplegia [65]. Interestingly, the
slow rate of motor neuron degeneration in Gde2 KOs is
similar to HSP and certain forms of Spinal Muscular
Atrophy [66, 67]. In addition, decreased expression of
Gde2 has been observed in laser captured motor neu-
rons from sporadic ALS patients [68]. These observa-
tions reinforce the compelling notion that GDE2
dysfunction may underlie aspects of human neurode-
generative disease. Moving forward, verifying GDE2
hypofunctionality in human disease will be of para-
mount importance, and elucidating the mechanisms by
which GDE2 regulates neuronal survival will be crucial
to develop strategies to mitigate neurodegeneration.
Conclusion
This report identifies GDE2 as a novel survival factor
for spinal neurons in the adult nervous system. Gde2
knock-out animals exhibit a progressive neurodegener-
ation marked by pathologies mirroring human disease.
Conditional ablation of Gde2 demonstrates that GDE2
functions postnatally to ensure neuronal health and
survival. In addition, we find that the production of
membrane released Glypicans, GPI-anchored substrates
of GDE2, is reduced in the SOD1G93A mouse model.
Our findings implicate diminished GDE2 function as a
novel component in the etiology of several diverse neu-
rodegenerative pathologies, and raise the possibility
that improper regulation of GPI-anchored GDE2 sub-
strates is mechanistically linked to neurodegeneration.
Additional files
Additional file 1: Figure S1. Sensory neurons exhibit
neurodegenerative pathology without impaired nerve conduction in the
absence of Gde2. This figure illustrates the presence of neuropathology in
the primary sensory neurons of the Gde2 KO, including vacuolization,
lipid accrual, and cytoskeletal accumulation; and the maintenance of
peripheral sensory nerve conduction. Figure S2-related to Fig. 9.
Conditional ablation of Gde2 in the postnatal spinal cord prevents the
developmental loss of motor neurons. This figure confirms the effective
conditional ablation of Gde2 following neurogenesis. In the constitutive
KO, GDE2’s absence during embryonic neurogenesis causes a reduction
of alpha motor neurons in the lateral motor column; however, in the
Gde2lox/-;ROSA:CreER animals, this loss is avoided by injecting 4-OHT at
E17.5. Further, competitive PCR analysis shows a near complete deletion
of the conditional Gde2 allele following 4-OHT delivery. Figure S3. Gde2
deletion does not perturb neuromuscular junction morphology. This
figure uses wholemount immunohistochemistry to assess the integrity of
the neuromuscular junction (NMJ) in aged Gde2 KO hindlimb muscle. At
19 months, no discernible pathology is present in the Gde2 KO NMJ.
(DOCX 6586 kb)
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